Integra LifeSciences sees FY23 adjusted EPS $3.43-$3.51, consensus $3.52

Sees FY23 revenue $1.602B-$1.620B, consensus $1.62B. The Company’s guidance for 2023 revenue and adjusted earnings per share reflects the recovery of our markets back to pre-COVID levels, a gradual improvement in supply over the year, the relaunch of CereLink in the first half, and the impact of our commercial capability build-out and new products. The guidance also reflects the recent acquisition of DuraSorb as well as the divestiture of the TWC business. The company said, "Our guidance reflects a sequential improvement from first to second half growth primarily driven by the gradual recovery of supply throughout the year, 2022 normalization from our private label business, the recovery of our China business post-COVID lockdowns, and the timing of the CereLink relaunch. The acquisition of DuraSorb and divestiture of the TWC business also contributed to the sequential step-up in growth."